EGFR and lung adenocarcinoma: More than half of EGFR-mutant lung adenocarcinomas have a concurrent TP53 mutation [11], and TP53 co-mutations are also frequent in tumors with ALK, ROS1, and RET fusions (approximately 25–50%, Table 1), [14,15].